While Novo’s GLP-1 meds post big gains, the company is still looking to create an insulin ‘revolution,’ CEO says

While Novo’s GLP-1 meds post big gains, the company is still looking to create an insulin ‘revolution,’ CEO says
fkansteiner
Fri, 08/06/2021 – 08:32